Objective: To examine in vivo levels of ␤-amyloid (A␤) oligomers (oA␤) vs monomeric A␤ in plasma and brain tissue of patients with sporadic and familial Alzheimer disease (AD) using a new enzyme-linked immunosorbent assay (ELISA) specific for oA␤.
A
LZHEIMER DISEASE (AD) IS characterized by the progressive accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles. The protein subunit of the amyloid plaques, ␤-amyloid (A␤), does not occur as a single molecular species; many different A␤-containing peptides have been detected in human cerebrospinal fluid (CSF) and/or brain tissue. 1, 2 The most common A␤ isoform in vivo is A␤ , ie, a peptide that begins at Asp1 and terminates at Val40 of the A␤ region of amyloid precursor protein (APP). Increased accumulation of A␤ , a peptide that differs from A␤ by the inclusion of Ile41 and Ala42, is particularly associated with development of AD. The extra 2 hydrophobic amino acids of A␤ 42 greatly enhance its aggregation propensity, 3 leading to accelerated formation of small (low-n) A␤ oligomers (oA␤), larger intermediate assemblies like protofibrils, and eventually the typical approximately 8-nm amyloid fibrils found abundantly in neuritic plaques and amyloid-bearing microvessels. Small, soluble oligomers of A␤ have been linked to neuronal toxic effects and synaptic failure (for review, see the article by Walsh and Selkoe 4 ). How the oligomeric assemblies reach a balance with monomeric A␤ and large protofibrils and fibrils in the human brain is under investigation.
Studies of circulating A␤ in blood have provided insights into A␤ equilibrium between the brain and the periphery. A few studies have associated increased levels of plasma A␤ 42 with AD at different stages. For example, an increase in the plasma A␤ 42 level was associated with conversion from normal cognition to mild cognitive impair-ment (MCI) and on to AD, albeit with unsatisfactory sensitivity and specificity. 5 Another study found that patients with AD at baseline and those who developed AD later had significantly higher plasma A␤ 42 levels; some of the patients with AD showed elevated levels of A␤ 42 and A␤ 40 before and during the early stages of AD, but plasma levels declined thereafter. 6, 7 Another study showed that nondemented subjects with high levels of plasma A␤ 42 were more than twice as likely to develop AD than those with low levels and that patients with AD showed higher A␤ 42 levels than control subjects without AD. 8 Patients with familial AD (FAD) having mutations in the presenilins, the catalytic subunits of the ␥-secretase complex that generates A␤, have increased plasma levels of A␤ 42 . 9 Plasma A␤ 42 levels and the A␤ 42 /A␤ 40 ratio were higher even in presymptomatic subjects carrying FAD mutations in presenilin 1 (PS1) or APP, and A␤ 42 levels may decrease with disease progression prior to symptom onset. 10 Elevated plasma A␤ 42 levels have been linked to a locus on chromosome 10 in some typical (late-onset) AD cases, 11 and some first-degree relatives of patients with late-onset AD have elevated A␤ 42 levels. These suggest that an increased plasma A␤ level is a heritable trait. 12, 13 Plasma A␤ is a potentially promising but understudied candidate marker for diagnosis and preclinical prediction. However, plasma A␤ 40 or A␤ 42 was found not to be an optimal candidate in unbiased proteomic searches for AD fluid biomarkers. 14, 15 In one study, 16 increased plasma A␤ 42 levels were detected in patients with MCI, but a significant association was only observed in women. In a cohort of men at age 70 years, plasma A␤ 40 and A␤ 42 were not associated with incident AD at follow-up, whereas low plasma A␤ 40 levels in another cohort of men at age 77 years were associated with a higher incidence of AD. 17 Yet another study 18 found that subjects with low plasma A␤ 42 /A␤ 40 ratios had a higher risk of MCI or AD and greater cognitive decline. A correlation between increased plasma A␤ 40 levels and an increased risk of dementia has also been reported. 19 A recent study of patients with MCI followed up for 7 years showed no significant difference of plasma A␤ species between patients with MCI who later developed AD and patients with stable MCI or healthy control subjects. 20 These often inconsistent reports on the association of plasma A␤ levels with AD may reflect the fact that measurements to date only represent the pools of monomeric A␤ and were measured by different A␤ enzymelinked immunosorbent assays (ELISAs). 21 To understand the relationship among different A␤ species in vivo, we developed an ELISA that can detect oA␤ and simultaneously measured both A␤ monomers and oA␤ in human plasma or postmortem brain tissue. Levels of human oA␤ detected by our new oA␤-specific ELISA were closely associated with the levels of monomeric A␤ 42 . Levels of both soluble and insoluble A␤ 42 and oA␤ species were significantly higher in brain tissue of patients with AD compared with those in brain tissue of control subjects. We also observed decreases in plasma A␤ levels in follow-up samples from the same patients 1 to 2 years later. The development of an oligomer-specific ELISA applicable to plasma extends A␤ measurement to a highly relevant neurotoxic form of this pathogenic peptide.
METHODS

PLASMA AND BRAIN LYSATE PREPARATION
Blood samples were collected in potassium-EDTA-containing collection tubes and centrifuged at 1600g for 15 minutes. The plasma supernatant was aliquoted and stored at −80°C until measured. Average ages for patients with AD and control subjects at the time of blood drawing were 72 years (n=36) and 62 years (n=10), respectively. Brain lysates from postmortem human brains (n=16) were prepared as recently described.
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ELISAs AND ANTIBODIES
Sandwich ELISAs for monomeric A␤ were performed as described. 23 The use of C-terminal capturing antibodies and Nterminal or midregion detecting antibodies has been a standard format for measuring monomeric A␤ species in many studies. 9, [24] [25] [26] The capture antibodies 2G3 (to A␤ residues 33-40) and 21F12 (to A␤ residues 33-42) were used for A␤ 40 and A␤ 42 species, respectively. The detecting antibodies were biotinylated 3D6 (to A␤ residues 1-5) for A␤ 1-40/42 or biotinylated 266 (to A␤ residues 13-28) for A␤ x-40/42 species. These antibodies were kindly provided by Peter Seubert, PhD, and Dale Schenk, PhD (Elan Corp, plc, South San Francisco, California).
To detect oA␤ species, the same N-terminal antibody, either 82E1 (to A␤ residues 1-16; Immuno-Biological Laboratories, Inc, Minneapolis, Minnesota) or 3D6, was used for both capture and detection. A sandwich ELISA procedure identical to that for the traditional monomer assays was followed to measure relative oA␤ levels, which were calculated using standard curves of synthetic A␤ 1-40 peptide captured by 2G3 antibody and measured by the same detecting antibodies (82E1 or 3D6).
STABLE CELL LINES AND CELL CULTURE
Chinese hamster ovary cells stably expressing wild-type (wt) human APP751 plus either wt or mutant PS1 (resulting in lines PS1 WT-1 , PS1 WT-2 , PS1 WT-3 , PS1 M146L-1 , PS1 M146L-2 , PS1 M146L-3 [M146L missense mutation], and PS1 C410Y-1 , PS1 C410Y-2 , PS1 C410Y-3 [C410Y missense mutation]) were maintained in 200-µg/mL G418 (Invitrogen Corp, Carlsbad, California) plus 25-µg/mL puromycin (for PS1). We also examined Chinese hamster ovary cell lines singly transfected with wt APP 751 or APP 751 bearing the V717F ("Indiana") missense mutation. Cells were incubated in methionine-free, fetal bovine serum-free media for 45 minutes before labeling with 200-µCi/mL sulfur 35 ([ 35 S])-labeled methionine for 38 hours (to convert microcuries per milliliter to becquerels per milliliter, multiply by 37 000). Conditioned media were collected and immunoprecipitation was performed as described.
25
PRODUCTION AND CHARACTERIZATION OF CROSS-LINKED A␤ DIMERS
␤-Amyloid dimers (dA␤) were generated by atmospheric oxidation of a 20µM solution of synthetic A␤ Ser26Cys in 20mM ammonium bicarbonate, pH 8.0, for 4 days at room temperature. To facilitate disassembly of aggregates formed during the oxidation reaction, the peptide solution was lyophilized and the lyophilate was incubated in 5M guanidine hydrochloride, 50mM TRIS hydrochloride, pH 8.0, for 4 hours. Disulfidecrossed-linked dA␤ were isolated from unreacted monomer and higher aggregates by size exclusion chromatography using a Superdex 75 10/30 high-resolution column (GE Healthcare, Milwaukee, Wisconsin) eluted with 50mM ammonium acetate, pH 8.5, at a flow rate of 0.8 mL/min. Fractions (0.5 mL) were collected, an aliquot of each was electrophoresed on 16% TRIStricine polyacrylamide gels, and protein was detected by silver staining. Size exclusion chromatography fractions found to exclusively contain dA␤ were pooled and used as the dimer stock.
The concentration of peptides in stock solutions was determined by comparison with wt A␤ 1-40 of known concentration. Once collected, all of the samples were stored at −80°C until used. To disrupt the disulfide bonds linking the monomers, dA␤ were treated with 3% ␤-mercaptoethanol (␤ME), followed by serial dilutions for quantification by ELISA. The diluted, residual amount of ␤ME did not interfere with the capture and detecting antibodies. The A␤ Ser26Cys was synthesized by the Biopolymer Laboratory, Department of Neurology, UCLA Medical Center, Los Angeles, California, and the correct sequence and purity were confirmed by amino acid analysis, reverse-phase high-performance liquid chromatography, and mass spectrometry.
RESULTS
ESTABLISHING AN oA␤-SPECIFIC ELISA
To analyze oA␤ species in human samples, we established a sensitive and specific oA␤ ELISA. The assay relies on the use of a single monoclonal antibody for both capture and detection. Thus, for oA␤ to be detected by this sandwich ELISA, an A␤ assembly must contain at least 2 exposed copies of the same epitope that is accessible by the identical capturing and detecting antibody. 27, 28 This means that this assay will recognize only A␤ assemblies that contain at least 2 A␤ molecules. Two monoclonal antibodies, 82E1 and 3D6, that each recognize the extreme N-terminus of human A␤ were tested.
To confirm the specificity of the ELISA, we used a synthetic A␤ peptide, A␤ Ser26Cys, that is capable of reversibly forming covalently cross-linked dA␤ under oxidizing conditions. 22, 29 Disulfide-crossed-linked dA␤ were Figure 1. Detection of low-molecular-weight oligomeric ␤-amyloid (A␤) (di-Cys synthetic dimer) by enzyme-linked immunosorbent assay (ELISA). A, Size exclusion chromatography fractions of A␤ dimers (dA␤) and synthetic monomeric A␤ (mA␤) were visualized on the same sodium dodecyl sulfate electrophoresis gel by silver staining. Based on the absolute amount of synthetic A␤ peptide loaded on the same gel, the concentration of dA␤ was calculated. ␤ME indicates ␤-mercaptoethanol; wt, wild-type. B, In the presence of ␤ME, dA␤ were dissociated into mA␤. Serial dilutions of dA␤ with and without ␤ME treatment were analyzed by ELISA using antibody 82E1 (C) or 3D6 (D). Error bars indicate SEM. Figure 2 . Measurements of the relative concentrations of oligomeric ␤-amyloid (oA␤) from patients with Alzheimer disease (AD) and control subjects by enzyme-linked immunosorbent assay. Most of the control subjects (7 of 10 subjects) have plasma levels of oA␤ below the detection limit, but many of the patients with AD (19 of 36 patients) have detectable oA␤ levels.
separated from unreacted monomer and higher aggregates by size exclusion chromatography. The concentration of dA␤ in stock solutions was determined by comparison with wt synthetic A␤ 1-40 of known concentration; both dA␤ and monomeric wt A␤ peptides were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining ( Figure 1A) . Based on the densitometric signal obtained from synthetic wt A␤ 1-40 peptide, we estimated that the concentration of our synthetic dA␤ stock was 81µM. In the presence of 3% ␤ME, the disulfide bonds linking the monomers that form dA␤ were disrupted, producing a reduced monomer ( Figure 1B ). In the absence of ␤ME, no monomeric A␤ was detected and the vast majority of A␤ species were dA␤ ( Figure 1B ).
Serial dilutions of dA␤ were made after the dA␤ stock was treated with or without ␤ME, and the diluted samples were assayed using either antibody 82E1 ( Figure 1C ) or antibody 3D6 ( Figure 1D ) in a sandwich format. When the relative levels of the diluted dA␤ (800pM) of the dA␤ stock were normalized to 1, either monoclonal antibody detected a clear linear reduction in the levels of dA␤ when further diluted to 400pM and 200pM ( Figure 1C ). In the presence of ␤ME, dissociation of the disulfide bond markedly reduced the amount of dA␤ signal; the levels of remaining dA␤ were less than 10% of the same fraction without ␤ME, with antibody 82E1 showing even greater specificity than antibody 3D6 in this regard ( Figure 1C and D) . Therefore, our new ELISA accurately measured the levels of dA␤ in a linear fashion and is highly sensitive to the dissociation of dA␤ to monomers.
QUANTIFYING PLASMA oA␤ FROM PATIENTS WITH AD
Using the oA␤-specific ELISA, we screened plasma samples obtained from 36 patients with wellcharacterized AD and 10 control subjects. The ages of the patients with AD ranged from 50 to 90 years at the time of blood sampling, with an average age of 72 years. The age of control subjects ranged from 52 to 68 years, with an average age of 62 years. Conventional A␤ ELISAs were applied to measure monomeric A␤ species.
We analyzed plasma levels of oA␤ as a function of subject age but did not observe an age-dependent alteration of oA␤ levels (Figure 2 ). There were a number of subjects who carried high plasma levels of oA␤-reactive species, with a wide age distribution between 60 and 90 years. Overall, we found that most control subjects (7 of 10 subjects) had plasma levels of oA␤ below our detection limit, whereas more than half of the patients with AD (19 of 36 patients) had detectable oA␤ levels ( Figure 2) .
From the same aliquot of plasma, we measured 4 monomeric A␤ species using 4 distinct ELISAs: A␤ 1-40 , A␤ , and N-terminally heterogeneous A␤ 40 and A␤ 42 species (ie, A␤ x-40 and A␤ x-42 ). The levels of A␤ and A␤ x-40 did not reveal a clear separation of patients with AD from control subjects (Figure 3A and B). On average, the levels of A␤ x-40 were higher than those of A␤ (note scales on the ordinates of Figure 3A and B), indicating that a variable portion of plasma A␤ 40 is N-terminally truncated. When the levels of A␤ x-42 ( Figure 3C ) and A␤ ( Figure 3D ) were analyzed from the same aliquots of plasma, we found that the levels of A␤ 1-42 species were , and A␤ were measured by separate sandwich enzyme-linked immunosorbent assays using C-terminal-specific antibodies. The overall difference between the patients with AD and the control subjects is minimal for A␤ 40 . Most of the control subjects (9 of 10 subjects) have plasma levels of A␤ generally lower than those of A␤ species and that the levels of A␤ x-42 were likewise lower than those of A␤ x-40 (compare Figure 3A and B with Figure 3C and D).
CLOSE ASSOCIATION OF LEVELS OF MONOMERIC A␤ 42 AND oA␤ IN HUMAN PLASMA
We calculated the average plasma A␤ levels for each of the 4 ELISAs in all of the patients with AD and control subjects. Plasma levels of A␤ 40 and A␤ x-42 did not differ significantly between patients with AD and control subjects ( Figure 4A) . However, the average plasma levels of both A␤ and oA␤ were found to be significantly higher in patients with AD than in control subjects ( Figure 4A ). Furthermore, the relative levels of A␤ and oA␤ were closely associated. For this, we chose a threshold of 10pM for A␤ (ie, readily detectable above baseline) and identified 7 subjects who carried levels of A␤ greater than 10pM ( Figure 4B ). Next, we identified 7 subjects who carried higher levels of oA␤ than the remaining subjects ( Figure 4C ). We found that the subjects who carried levels of A␤ 1-42 greater than 10pM ( Figure 4B ) were the same subjects who carried high levels of oA␤ ( Figure 4C ), and the relative levels of A␤ and oA␤ for each subject were tightly linked. Except in 1 patient who had the highest oA␤ level ( Figure 4C ) but had a relatively low A␤ 1-42 level ( Figure 4B ), our oA␤ ELISA clearly detected oA␤-reactive species whose levels were tightly associated with those of monomeric A␤ .
CONCOMITANT INCREASES OF MONOMERIC A␤ 42 AND oA␤ IN CULTURED CELLS
To further validate the close association of monomeric A␤ 42 with oA␤ detected by our oA␤ ELISA, we analyzed these A␤ species generated from cell lines expressing FAD-causing mutations in either APP or PS1. These cell lines have elevated A␤ 42 monomer levels and secrete sodium dodecyl sulfatestable, low-n A␤ oligomers into the media. 25, 30, 31 Similar to our AD and control cases that carry different levels of plasma A␤, we have found variable levels of A␤ produced from multiple stable cell lines expressing wt or mutant (M146L or C410Y) PS1 and wt or mutant (V717F) APP. These lines were metabolically labeled with [
35 S]methionine, and the conditioned media were immunoprecipitated with antibody 21F12 (to A␤ ending at residue 42) or 1282 (a pan-A␤ polyclonal antibody) and analyzed by gel fluorography. Antibody 21F12 immunoprecipitated both monomeric A␤ 42 and the p3 42 species (generated by sequential ␣-and ␥-secretase cleavages of APP) from the conditioned media of all of the cell lines. In media from APP V717F and PS1 M146L-2 cells, additional A␤ 42 -immunoreactive bands migrating at approximately 5 kDa, 8 to 10 kDa, and 12 to 14 kDa (collectively designated sodium dodecyl sulfate-stable, low-n oligomers) were also detected ( Figure 5A ). Light exposure of blots separating A␤ 42 monomers from oA␤ indicated that more A␤ 42 was produced from cells expressing APP V717F or mutant PS1 (PS1 M146L-2 ) ( Figure 5B ). The levels of oA␤ were correlated with the levels of monomeric A␤ 42 , ie, the cell lines secreting elevated A␤ 42 also had higher levels of oligomers in their media. We further examined the levels of total A␤ precipitated by antiserum 1282 but did not observe an elevation in total A␤ signal corresponding to those of A␤ 42 and oA␤. Thus, the amounts of total A␤ generated by cells expressing APP V717F or mutant PS1 (PS1 M146L-2 ) were comparable to those from the other cell lines ( Figure 5C ). Moreover, no oA␤ species were detected in these immunoprecipitates of total A␤, suggesting that the oA␤ species made by the cells are principally composed of A␤ 42 . These results in well-defined cultured cell lines support our finding in human plasma that levels of oA␤ are closely associated with those of monomeric A␤ 42 .
DECLINING PLASMA A␤ 42 LEVELS OVER 1 TO 2 YEARS
The close association of monomeric A␤ 42 and oA␤ levels suggests a dynamic conversion between these 2 A␤ species. To further examine the relationship of A␤ 42 and oA␤ in vivo, we obtained sequential blood samples from a patient with symptomatic FAD carrying a mutant PS1. Blood samples were drawn at ages 58 and 60 years. Levels of A␤ were quantified by separate ELISAs for oA␤ and the 4 monomeric A␤ species (Table) . For oA␤ species, we observed a significant decrease such that oA␤ was no longer detectable at age 60 years. For monomeric A␤, the plasma concentrations of A␤ and A␤ x-40 were 48pM and 84pM, respectively, at age 58 years. The concentration of A␤ 1-42 was 7pM, and that of A␤ x-42 was 36pM. The plasma A␤ 42 /A␤ total ratio was in the same range as those reported in patients carrying FAD-causing PS1 mutations. 9 Plasma samples collected 22 months later had significantly lower A␤ concentrations: the level of A␤ 1-40 measured 36pM (25% reduction), and A␤ 1-42 was now undetectable (Table) . Concentrations of A␤ x-40 and A␤ x-42 declined to 48pM (43% reduction) and 15pM (58% reduction), respectively. Thus, while the levels of both A␤ species decreased over 2 years, A␤ 42 -ending species were reduced more dramatically than A␤ 40 -ending species. The complete loss of the A␤ and oA␤ signals is consistent with our findings that the levels of these 2 species are closely associated.
We also obtained sequential blood samples from a subset of our patients with AD (n=12, including the patient with FAD described earlier) and compared their A␤ levels over a 1-to 2-year span. All of the 5 A␤ species were again measured by ELISA and the changes in A␤ levels were calculated. A similar number of subjects showed increased or decreased levels of A␤ over the course of 1 to 2 years ( Figure 6A) , failing to show a clear temporal trend in A␤ . Comparison of A␤ x-40 levels revealed that 3 of 11 subjects had an increased A␤ x-40 level and the remaining 8 subjects had a reduced A␤ x-40 level ( Figure 6B ). In the 4 patients with AD who had detectable plasma A␤ 1-42 levels ( Figure 6C ), 3 subjects showed a dramatic reduction in the A␤ 1-42 level after 1 year but 1 subject had almost identical levels of A␤ 1-42 at both times. The latter subject also maintained similar levels of oA␤ after 1 year, whereas 4 patients with AD with detectable oA␤ levels had a reduction in the relative plasma oA␤ level ( Figure 6E) . Thus, the decrease of A␤ 1-42 levels occurred in subjects who also showed a similar decrease in oA␤ levels. Strikingly, all but 1 subject showed decreases in A␤ x-42 in the second plasma samples ( Figure 6D ).
ELEVATED LEVELS OF MONOMERIC A␤ 42 AND oA␤ IN BRAIN TISSUE OF PATIENTS WITH AD
To investigate the association of monomeric A␤ 42 and oA␤ directly in human brains, we obtained postmortem brain C410Y-3  wt APP   3  1 2 3  1 2 3  1 2 3 1 2 3  1  2  3  1 2 3  1  2  3  1 2 3  1 2 tissue from 9 patients with AD and 7 age-matched control subjects distinct from the subjects examined in the plasma A␤ studies described earlier. We performed sequential extractions of brain tissue to obtain "soluble" (TRISbuffered saline [TBS]) and "insoluble" (guanidine hydrochloride) extracts and measured their A␤ contents by ELISA.
The soluble pool of brain A␤ extracted by TBS had relatively low levels of A␤ (Figure 7A) ; an average of 1.1 pmol/g of A␤ was detected in the patients with AD vs 0.7 pmol/g in the control subjects (P=.14). The average level of TBS-soluble A␤ 1-42 was significantly higher in patients with AD than in control subjects ( Figure 7B) . Likewise, the relative levels of TBS-soluble oA␤ were significantly higher in patients with AD as most control subjects had almost undetectable levels of soluble oA␤ ( Figure 7C ).
After the extraction of soluble A␤ by TBS, the resultant pellets were further extracted in guanidine hydrochloride to obtain the insoluble pools of A␤. Overall, insoluble A␤ 1-42 levels ( Figure 7E ) were several hundred-fold higher than soluble A␤ 1-42 levels ( Figure 7B ), and they were almost 10-fold higher than insoluble A␤ 1-40 levels ( Figure 7D ). This is consistent with numerous previous reports that amyloid deposits in brain tissue of patients with AD are mainly composed of A␤ 42 . The levels of both insoluble A␤ 1-40 and insoluble A␤ were significantly higher in brain tissue from patients with AD than those in brain tissue from control subjects. Furthermore, a substantial and significant increase in the relative levels of insoluble oA␤ was observed in brain tissue of patients with AD ( Figure 7F ). Importantly, brain tissue levels of insoluble A␤ were closely associated with the levels of oA␤ in both patients with AD and control subjects (for AD: correlation coefficient = 0.88; for control subjects, correlation coefficient=0.98). For example, 1 patient with AD (patient 4) showed relatively low levels of A␤ 1-42 , and accordingly the oA␤ level was low. A control subject (subject 3) showed a relatively high level of A␤ 1-42 , corresponding to a high level of oA␤ ( Figure 7F ). On average, significantly higher levels of all of the 3 insoluble A␤ species (A␤ 1-40 , A␤ , and oA␤) were found in brain tissue of patients with AD compared with those in brain tissue of control subjects ( Figure 7D-F) .
COMMENT
Given the burgeoning evidence that small oligomeric assemblies of A␤ may be principally responsible for neu- ronal dysfunction in AD, it is important to be able to specifically detect and quantify these species in a range of biological samples. Conventional approaches to measuring the levels of oA␤ have focused on semiquantitative analysis by Western blotting or silver staining of sodium dodecyl sulfate-polyacrylamide gel. Recent advances in nanotechnology have enabled the measurement of subpicomolar concentrations of oligomers (also designated A␤-derived diffusible ligands) in human CSF. 32 For ELISA-based approaches, several groups have generated antibodies believed to be specific for aggregated A␤. Among them, monoclonal antibody NAB61 specifically recognizes a complex conformational A␤ 1-11 epitope on peroxynitrite-or UV light-treated synthetic A␤, with much less reactivity for monomeric A␤. Using NAB61 as a capture antibody and another A␤ antibody (BA27) as a reporter, this sandwich ELISA can differentiate UVcross-linked synthetic A␤ from monomeric synthetic A␤ with a relative sensitivity of 5:1. 33 Another antibody (158) recognizes 50-to 200-kDa protofibrillar aggregates of synthetic A␤ but not low-molecular-weight oligomers and monomers of synthetic A␤. 34 In this study, we oxidized synthetic A␤ Ser26Cys peptide to generate disulfide-crossed-linked dimers to test our new oA␤ ELISA. The A␤ Ser26Cys dimer preparation was treated with guanidine hydrochloride and therefore was free of any higher-molecular-weight aggregates ( Figure 1B) . Subsequent separation of the stable dimers from un-cross-linked monomers was achieved by size exclusion chromatography. Detection of the synthetic dimers only in the absence of ␤ME clearly demonstrated the specificity of our oA␤ ELISA, with far less ability to detect monomers.
Using this new oA␤ ELISA and previously established monomeric A␤ ELISAs, we obtained several lines of evidence for a close association between the levels of monomeric A␤ 42 and oA␤ species in human plasma and brain tissue. First, the close association of A␤ and oA␤ was observed in a subset of patients with AD who had readily detectable levels of plasma A␤ (Figure 4) . The average levels of these 2 A␤ species were significantly higher in the patients with AD than in the control subjects. Indeed, only 1 of 10 control subjects showed such readily detectable levels of A␤ . Second, our studies of brain tissue from patients with AD and control subjects showed the same pattern, ie, levels of insoluble A␤ associated closely with the relative levels of insoluble oA␤ across individual cases (Figure 7) . Third, among all of the patients with AD and control subjects, higher levels of oA␤ were not linked to lower levels of monomeric A␤ 42 , suggesting that the conversion of monomeric A␤ into oA␤ per se is not the major contributor to the observed reduction of monomeric A␤ 42 . Overall, our oA␤-specific ELISA allowed us to establish a close quantitative relationship between the levels of A␤ and oA␤ in human plasma and brain tissue.
This association was also observed in cultured cells expressing human APP. We found that the appearance of soluble oA␤ in the medium occurred exclusively in those clonal cell lines with significantly increased A␤ 42 monomer production ( Figure 5 ). The FAD mutations in PS1 or APP lead to enhanced A␤ 42 generation, and the occurrence of oA␤ is attributable to enhanced ␥-secretase cleavage of APP at the 42nd residue of A␤, which is facilitated by AD-causing mutations in either the substrate (APP) or the protease (PS1). Thus, levels of A␤ 42 are closely associated with the formation of oA␤.
Our longitudinal comparisons of individual patients with AD provide new insight into the dynamic changes in plasma A␤ levels without the problem of intersubject variation. Using monomeric A␤ and oA␤ ELISAs, we have provided 2 snapshots of A␤ levels within a relatively short period. Whereas we saw no clear directional change of A␤ 1-40 levels, the levels of the remaining 4 A␤ species all showed a reduction over the course of 1 to 2 years. About three-quarters of cases showed a reduction in A␤ x-40 levels. Among the cases with detectable plasma levels of A␤ and oA␤, all but 1 showed a decrease in A␤ levels. In the case of A␤ x-42 , 9 patients showed a reduction over the 1-to 2-year period, whereas 1 patient showed an increase. Importantly, the individuals with decreasing A␤ 1-42 monomer levels were the same subjects who showed decreases in oA␤ levels.
While our oA␤ ELISA provides an accurate method to measure such species in human blood, our results do not yet validate any one A␤ species as a biomarker for AD. Currently, the CSF tau/A␤ 42 ratio has been the best predictor of the development of AD-type cognitive decline in stillnondemented subjects. 35, 36 Changes in the levels of tau and A␤ 42 in CSF may reflect dysfunction in the cerebrum that can be measured by the electroencephalographic rhythm, 37 and low A␤ 42 levels in CSF correlate well with positive Pittsburgh Compound B uptake by positron emission tomographic scanning. 35 Precise measurement of A␤ in plasma and CSF and subsequent correlation with levels in postmortem brain tissue should yield a clearer picture of A␤ metabolism in vivo. Mathematic modeling of the equilibrium between monomeric A␤ and oA␤ would also help elucidate the catabolic turnover of A␤ in the peripheral and central nervous systems. 38 Considering a wide range of factors that could contribute to variations in plasma A␤ levels, it is currently difficult to obtain a clear separation of patients with AD from control subjects simply by measuring the levels of plasma A␤ species. 39 However, our findings suggest that measuring plasma A␤ and oA␤ over 1 to 2 years or more can reveal a significant reduction in plasma A␤ levels, especially A␤ 42 levels, and this finding raises the possibility of a direct relationship of plasma A␤ to brain amyloid formation. 
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